巴西成人健康纵向研究(ELSA-Brasil)队列中左甲状腺素治疗期间的促甲状腺激素轨迹
该研究基于ELSA-Brasil队列中621名接受左甲状腺素治疗的参与者,采用生长混合模型(GMM)和潜类别增长分析(LCGA)根据连续促甲状腺激素(TSH)水平划分轨迹类别,并分析各类别的心血管健康标志物变化。识别出4种TSH轨迹类别,基线时各类别心血管标志物无显著差异,但所有类别在随访期间至少有一项心血管标志物出现显著变化。
要点
- 基于TSH轨迹可识别出4类左甲状腺素治疗患者。
- 高-高正常TSH组基线左甲状腺素平均剂量最低(77.7 µg,P < .001)。
- 低至正常TSH组的总胆固醇、高密度脂蛋白胆固醇、甘油三酯和糖化血红蛋白均显著升高。
核心结论
- GMM/LCGA是定义和检查左甲状腺素治疗TSH轨迹的可行方法。
- 更全面的数据集应允许更复杂的轨迹建模和轨迹类别间临床结局差异的分析。
研究设计与样本
- 本研究为原理验证研究,使用来自大型前瞻性研究(ELSA-Brasil)的纵向临床数据,包括甲状腺激素水平。
- 共纳入621名接受左甲状腺素治疗的参与者,采用生长混合模型(GMM)包括潜类别增长分析(LCGA)根据连续TSH水平进行分类。
- 采用重复测量分析评估类别内血压、血脂、糖化血红蛋白和心血管相关药物使用的变化。
主要发现
- 从621名接受左甲状腺素治疗的参与者中,最佳拟合GMM方法识别出4种TSH轨迹类别:高-高正常TSH、正常TSH、正常至低TSH、低至正常TSH。
- 基线时高-高正常TSH组的左甲状腺素平均剂量最低(77.7 µg,P < .001)。
- 基线时各类别间心血管健康标志物无显著差异。
- 所有类别中至少有一项心血管标志物出现显著差异,其中低至正常TSH组的总胆固醇、高密度脂蛋白胆固醇、甘油三酯和糖化血红蛋白均显著升高(P = .049,P < .001,P < .001,P = .001)。
- 所有类别中抗高血压药、抗高血脂药和抗糖尿病药的使用均增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Thyroid-stimulating hormone (TSH) trajectory classification represents a novel approach to defining the adequacy of levothyroxine (LT4) treatment for hypothyroidism over time. OBJECTIVE: This is a proof of principle study that uses longitudinal clinical data, including thyroid hormone levels from a large prospective study to define classes of TSH trajectories and examine changes in cardiovascular (CV) health markers over the study period. METHODS: Growth mixture modeling (GMM), including latent class growth analysis (LCGA), was used to classify LT4-treated individuals participating in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) based on serial TSH levels. Repeated measure analyses were then utilized to assess within-class changes in blood pressure, lipid levels, hemoglobin A1c, and CV-related medication utilization. RESULTS: From the 621 LT4-treated study participants, the best-fit GMM approach identified 4 TSH trajectory classes, as defined by their relationship to the normal TSH range: (1) high-high normal TSH, (2) normal TSH, (3) normal to low TSH, and (4) low to normal TSH. Notably, the average baseline LT4 dose was lowest in the high-high normal TSH group (77.7 µg, P < .001). There were no significant differences in CV health markers between the classes at baseline. At least 1 significant difference in CV markers occurred in all classes, highlighted by the low to normal class, in which total and high-density lipoprotein cholesterol, triglycerides, and A1c all increased significantly (P = .049, P < .001, P < .001, and P = .001, respectively). Utilization of antihypertensive, antihyperlipidemic, and antidiabetes medications increased in all classes. CONCLUSION: GMM/LCGA represents a viable approach to define and examine LT4 treatment by TSH trajectory. More comprehensive datasets should allow for more complex trajectory modeling and analysis of clinical outcome differences between trajectory classes.
引用
- Ettleson MD, Penna GCE, Wan W, et al. TSH Trajectories During Levothyroxine Treatment in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) Cohort. J Clin Endocrinol Metab. 2024. PMID: 38780968. doi:10.1210/clinem/dgae294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。